Why is Genmab stock surging today?

Genmab's stock rose 13.2% to DKK 2,992 after presenting positive Phase 2 trial results for petosemtamab in colorectal cancer. The data showed high response rates, and the company announced a new clinical trial collaboration with Incyte. JPMorgan raised its price target by 70% and upgraded its rating to 'Overweight'. The broader market had minimal impact on the stock's performance.

Original reporting
Published Oct 26, 2026, 8:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 9:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The fresh Phase 2 data and analyst upgrade create a strong short-term catalyst, likely extending the intraday rally.

02

Market read

A rare combination of trial data and analyst upgrade moves the stock sharply, offering immediate trading opportunity.

03

What to watch

Potential regulatory hurdles and competition from other KRAS inhibitors could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Genmab (GMAB) is a Danish biotech focused on antibody therapeutics, listed on Nasdaq via ADR.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab disclosed updated Phase 2 trial results for petosemtamab, driving a 13.2% stock surge.

Expected impact

likely upward pressure as market prices in the favorable data and analyst upgrade

Evidence & confidence

New efficacy data and a 70% target price increase provide fresh, material catalyst.

Market effects

Biotech sector may see broader rally on strong colorectal cancer data.

European biotech stocks could benefit from the positive European Society for Medical Oncology presentation.

Highlights growing interest in bispecific antibodies, potentially influencing global biotech valuations.

Counterpoint

Some investors may wait for Phase 3 confirmation before committing, citing historical trial attrition.

Key entities

  • Genmab

    Danish biotech company developing bispecific antibodies.

  • JPMorgan

    Raised price target by 70% and upgraded to Overweight.

Related articles

$GMABHighAI 8/10

Genmab (GMAB) Q3 2026 Earnings Call Transcript

Genmab reported positive phase III trial results for Epkinly, Rina-S, and petosemtamab, with Epkinly showing a hazard ratio of 0.49 in the EPCORE DLBCL-2 trial. Sales for Epkinly and Tivdak grew 47% and 9% year-over-year, respectively, to $491M and $131M in the first nine months of 2026. The company is preparing for potential launches in early lines of DLBCL and other indications.

$GMABMedAI 8/10

Why is Genmab stock sliding today?

Genmab (GMAB) shares fell 4.9% after Q3 revenue of $1.19B missed estimates, though EPS beat. Epkinly sales grew 47% but lagged Jyske Bank's forecast. Full-year guidance remained unchanged, disappointing some analysts. Higher costs reduced net profit. The company maintained its revenue and earnings outlook but did not raise it, despite recent clinical trial successes.